US Supply Of OTC COVID-19 Tests Gets Boost Through $231.8M Contract For Australian Firm
Biden administration seems to be betting Elluve's OTC at-home antigen diagnostic test will be a game changer in helping stop the spread of the coronavirus.
You may also be interested in...
Complaint filed in Maryland federal court says Australian firm, which received more than $230 from US government to boost production of its OTC COVID-19 diagnostic tests available to US consumers, should’ve offered refunds to consumers who bought tests the company has recalled due to false positive tests.
Developer Of First US OTC COVID-19 Antigen Test Plans 'Digital Diagnostics For Multitude Of Infectious Diseases'
The developer of the OTC at-home antigen test — the first of its kind to get an emergency use authorization from the FDA – received more than $200m from the US government to manufacture in the US. So what’s next for Ellume? In this Q&A, the Australian company’s CEO, Sean Parson, explains.
“We see this is a as a significant opportunity, and quite frankly, a trend that's been happening overseas and is kind of now happening here in the US,” says Abbott Labs CEO Robert Ford.